9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Third-generation EGFR-TKIs are designed to specifically inhibit mutant EGFR (19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.
“These agents are designed to specifically inhibit mutant EGFR (ie, 19del-EGFR, L858R-EGFR and/or T790M+EGFR), sparing the WT receptor.14–18”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [18]
The T790M mutation was observed in approximately 50% of cases in which biopsy was obtained at relapse following gefitinib or erlotinib treatment in patients with exon 19 deletion or L858R EGFR mutation.
“The presence of the T790M mutation was observed in approximately 50% of the cases in which biopsy was obtained at the time of relapse following gefitinib or erlotinib treatment in patients with the exon 19 deletion or the L858R EGFR mutation.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [18]
Cited by
Sorted by citations
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850 · see citing works
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000060 · Cited by 476 · see citing works
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Tan, C., Gilligan, D., & Pacey, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00246-6 · Cited by 390 · see citing works
Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 57 · see citing works
“NSCLC patients with deletion polymorphisms or l w-t -intermediate levels of BIM RNA have poor clinical efficacy under EGFR-TKIs [77,78].”
BackgroundRicciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39 · see citing works
Wang, L., Zhao, J., Yao, Y., Wang, C., Zhang, J., Shu, X. H., Sun, X., Li, Y., Liu, K., Yuan, H., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.024 · Cited by 39 · see citing works
Wang, Y., Guo, Z., Yang, L., & Zhou, Q. (2016) · Open Medicine · doi:10.1515/med-2016-0014 · Cited by 15 · see citing works
New strategies to develop new medications for lung cancer and metastasis
Zhao, Y., & Adjei, A. A. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9553-5 · Cited by 14 · see citing works
Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, E. H., & Horn, L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0365-1 · Cited by 12 · see citing works
- Authors
- Murakami, H., Nokihara, H., Shimizu, T., Seto, T., Keating, A., Krivoshik, A., Uegaki, K., Morita, S., Nakagawa, K., & Fukuoka, M.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 50
- Pages
- 198
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2169104752
- Cited by
- 9
- References
- 0
- Citations by year
- 2023: 1 · 2017: 2 · 2016: 3 · 2015: 3
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Cancer (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Cancer Mechanisms and Therapy
- Keywords
- non-small cell lung cancer, EGFR activating mutations, T790M mutation, anticancer activity, EGFR mutation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
